Post Operative Pain Management Through Adductor Canal Block With Bupivacaine for ACL Reconstruction

NCT ID: NCT05161221

Last Updated: 2021-12-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

154 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-06

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Liposomal bupivacaine injectable suspension (Exparel), manufactured by Pacira Pharmaceuticals, is an FDA-approved, long-lasting nonopioid analgesic that is indicated for single-dose infiltration in adults to produce postsurgical local analgesia. Exparel's extended bioavailability allows for 48 hours of pain control. Periarticular infiltration of liposomal bupivacaine has been safely and effectively used for total knee arthroplasty as an alternative to FNBs, avoiding transient quadriceps weakness and potential in-hospital falls. Recently Exparel has been FDA approved for interscalene brachial plexus nerve block to produce postsurgical regional analgesia for upper extremity/shoulder procedures. It is not yet approved for peripheral nerve blocks of the lower extremity.

No study to date, to our knowledge, has evaluated the efficacy of single-dose adductor canal blockade with Exparel compared to femoral nerve catheter with bupivacaine. We pose that Exparel used for an adductor canal block can offer the benefit of a single-dose injection with extended pain control without the burden of an indwelling catheter and to avoid adverse events of femoral nerve blockade related to quadriceps weakness and dysesthesias.

The purpose of this study is to determine whether adductor canal blockade with liposomal bupivacaine (Exparel) is a safe and effective alternative to femoral nerve catheters for post-operative pain control for patients undergoing ACL reconstruction.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain, Postoperative ACL

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pre-operative femoral nerve catheter

participants undergoing ACL reconstruction surgery will receive a femoral prior to their surgery

Group Type ACTIVE_COMPARATOR

OxyCODONE 5 mg Oral Tablet

Intervention Type DRUG

Participants will receive 20 OxyCODONE 5 mg Oral Tablet post surgery for pain control

Naproxen 500 Mg

Intervention Type DRUG

Participant will receive Naproxen 500 Mg post surgery for pain control

Tylenol Pill

Intervention Type DRUG

Participants will be instructed to take up to 1000mg of Tylenol by mouth for pain control

Femoral Nerve Catheter

Intervention Type PROCEDURE

Participants will receive pre-operative femoral nerve catheter

Pre-operative adductor canal block with liposomal bupivacaine

participants undergoing ACL reconstruction surgery will receive a nerve block using liposomal Bupivacaine (Exparel)

Group Type ACTIVE_COMPARATOR

OxyCODONE 5 mg Oral Tablet

Intervention Type DRUG

Participants will receive 20 OxyCODONE 5 mg Oral Tablet post surgery for pain control

Naproxen 500 Mg

Intervention Type DRUG

Participant will receive Naproxen 500 Mg post surgery for pain control

Tylenol Pill

Intervention Type DRUG

Participants will be instructed to take up to 1000mg of Tylenol by mouth for pain control

Liposomal bupivacaine

Intervention Type DRUG

Participants will receive pre-operative adductor canal block with liposomal bupivacaine (Exparel)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OxyCODONE 5 mg Oral Tablet

Participants will receive 20 OxyCODONE 5 mg Oral Tablet post surgery for pain control

Intervention Type DRUG

Naproxen 500 Mg

Participant will receive Naproxen 500 Mg post surgery for pain control

Intervention Type DRUG

Tylenol Pill

Participants will be instructed to take up to 1000mg of Tylenol by mouth for pain control

Intervention Type DRUG

Liposomal bupivacaine

Participants will receive pre-operative adductor canal block with liposomal bupivacaine (Exparel)

Intervention Type DRUG

Femoral Nerve Catheter

Participants will receive pre-operative femoral nerve catheter

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Exparel Femoral Nerve Block

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients undergoing primary anterior cruciate ligament reconstruction with autograft
2. Has not used narcotic pain medication in 3 months
3. Ages of 18+
4. Proficient in the English language
5. Willing and able to follow study protocol

Exclusion Criteria

1. ACL repair, revision surgery, or allograft
2. Multi-ligamentous knee injuries
3. Cartilage procedures that prevented adherence to the immediate weightbearing and range of motion rehabilitation protocol
4. Patients taking baseline opioid for other injury
5. Dementia or other psychiatric illness that would preclude accurate evaluation
6. Pregnant or lactating patients
7. Non-English speakers as questionnaires are only available in English
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rothman Institute Orthopaedics

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rothman Orthopaedic Institute

Philadelphia, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

sham21D.369

Identifier Type: -

Identifier Source: org_study_id